The city of Aurora, Colorado, currently has 8 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/24/2024
Locations: University of Colorado School of Medicine, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/24/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/19/2024
Locations: University of Colorado Anschutz Medical Campus - Department of Family Medicine, Aurora, Colorado
Conditions: Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: University of Colorado Anschutz Medical Campus - Department of Family Medicine, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
Recruiting
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Pulmonary Fibrosis, COVID-19, Long COVID, Post-acute Respiratory Complications of COVID-19
The Genetics of Pulmonary Fibrosis
Recruiting
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Advancing Prevention of Pulmonary Fibrosis
Recruiting
This study plans to learn more about pulmonary fibrosis and how it develops. We want to determine if the disease can be detected early, before the lung is permanently scarred. This study will enroll participants who are not currently diagnosed with pulmonary fibrosis, but who have family members with pulmonary fibrosis. Because there is an increased risk within affected families, this cohort will allow us to learn how pulmonary fibrosis develops, and how the lungs change over time.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
09/27/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: IPF, Pulmonary Fibrosis, ILD
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis... Read More
Gender:
All
Ages:
All
Trial Updated:
09/11/2020
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia